Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
Phase 2
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Registration Number
- NCT00097331
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 261
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of new gadolinium-enhancing lesions on monthly MRI scans
- Secondary Outcome Measures
Name Time Method Expanded Disability Status Scale (EDSS) and MS Functional Composite (MSFC) Number of other lesion types on MRI Number of relapses during treatment Circulating lymphocyte and neutrophil counts Health Outcomes: MSIS-29, Employment status
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does SB-683699 target in relapsing-remitting multiple sclerosis?
How does SB-683699 compare to beta-interferons in treating relapsing MS patients?
What biomarkers were used to assess response to SB-683699 in phase 2 MS trials?
What adverse events were observed in NCT00097331 and how were they managed?
Are there combination therapies involving SB-683699 for relapsing-remitting MS?
Trial Locations
- Locations (1)
GSK Investigational Site
🇪🇸Malaga, Spain
GSK Investigational Site🇪🇸Malaga, Spain